TY - JOUR
T1 - Two cases of dabrafenib and trametinib therapy-failed advanced melanoma successfully controlled by nivolumab monotherapy
AU - Sato, Yota
AU - Fujimura, Taku
AU - Kambayashi, Yumi
AU - Tanita, Kayo
AU - Tono, Hisayuki
AU - Hashimoto, Akira
AU - Aiba, Setsuya
PY - 2018/9
Y1 - 2018/9
N2 - Although therapies for advanced melanoma have been greatly improved by the development of immune checkpoint inhibitors and BRAF/mitogen-activated protein kinase kinase inhibitors, there are still many concerns about the administration of these novel drugs. Therefore, to combine these therapies sequentially at appropriate time points of the disease is important. In this report, we report two cases in which dabrafenib and trametinib therapy for advanced melanoma failed but were successfully controlled by nivolumab monotherapy, and investigated the sera sCD163, CCL22 and CXCL10 as biomarkers for tumor progression. Interestingly, the sera levels of sCD163, CXCL10 and CCL22, both of which are produced by activated tumor-associated macrophages, were increased in parallel with the tumor progression in each case. Because this report presents only two cases, further data will need to be accumulated to provide more fundamental insights into the usefulness of these biomarkers for predicting disease progression in melanoma.
AB - Although therapies for advanced melanoma have been greatly improved by the development of immune checkpoint inhibitors and BRAF/mitogen-activated protein kinase kinase inhibitors, there are still many concerns about the administration of these novel drugs. Therefore, to combine these therapies sequentially at appropriate time points of the disease is important. In this report, we report two cases in which dabrafenib and trametinib therapy for advanced melanoma failed but were successfully controlled by nivolumab monotherapy, and investigated the sera sCD163, CCL22 and CXCL10 as biomarkers for tumor progression. Interestingly, the sera levels of sCD163, CXCL10 and CCL22, both of which are produced by activated tumor-associated macrophages, were increased in parallel with the tumor progression in each case. Because this report presents only two cases, further data will need to be accumulated to provide more fundamental insights into the usefulness of these biomarkers for predicting disease progression in melanoma.
KW - chemokines
KW - dabrafenib and trametinib
KW - nivolumab
KW - sCD163
KW - tumor-associated macrophages
UR - http://www.scopus.com/inward/record.url?scp=85052567449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052567449&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.14508
DO - 10.1111/1346-8138.14508
M3 - Article
C2 - 29923635
AN - SCOPUS:85052567449
VL - 45
SP - 1105
EP - 1108
JO - Journal of Dermatology
JF - Journal of Dermatology
SN - 0385-2407
IS - 9
ER -